BRPI0519420A2 - anticorpo, composiÇço, mÉtodos para reconstituiÇço de lise mediada por cÉlula nk de uma cÉlula alvo em uma populaÇço, para avaliaÇço de um anticorpo contra nkg2a de humano, para produÇço de um anticorpo, para identificaÇço de um regime de administraÇço adequado para um anticorpo terapÊutico, para matanÇa de uma cÉlula nk, reduÇço da atividade de uma cÉlula nk, reduÇço da proliferaÇço de cÉlulas nk, prevenÇço da lise de cÉlulas suscetÍveis À lise por cÉlula nk, ou reduÇço do némero de cÉlulas nk em uma populaÇço, e para detecÇço da ligaÇço de um anticorpo em nkg2a, uso de uma composiÇço, conjugado, e, kit - Google Patents

anticorpo, composiÇço, mÉtodos para reconstituiÇço de lise mediada por cÉlula nk de uma cÉlula alvo em uma populaÇço, para avaliaÇço de um anticorpo contra nkg2a de humano, para produÇço de um anticorpo, para identificaÇço de um regime de administraÇço adequado para um anticorpo terapÊutico, para matanÇa de uma cÉlula nk, reduÇço da atividade de uma cÉlula nk, reduÇço da proliferaÇço de cÉlulas nk, prevenÇço da lise de cÉlulas suscetÍveis À lise por cÉlula nk, ou reduÇço do némero de cÉlulas nk em uma populaÇço, e para detecÇço da ligaÇço de um anticorpo em nkg2a, uso de uma composiÇço, conjugado, e, kit

Info

Publication number
BRPI0519420A2
BRPI0519420A2 BRPI0519420-2A BRPI0519420A BRPI0519420A2 BR PI0519420 A2 BRPI0519420 A2 BR PI0519420A2 BR PI0519420 A BRPI0519420 A BR PI0519420A BR PI0519420 A2 BRPI0519420 A2 BR PI0519420A2
Authority
BR
Brazil
Prior art keywords
cell
antibody
reducing
population
lysis
Prior art date
Application number
BRPI0519420-2A
Other languages
English (en)
Inventor
Alessandro Moretta
Emanuela Marcenaro
Francois Romagne
Pascale Andre
Original Assignee
Innate Pharma
Univ Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36350427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0519420(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma, Univ Genova filed Critical Innate Pharma
Publication of BRPI0519420A2 publication Critical patent/BRPI0519420A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

ANTICORPO, COMPOSIÇçO, MÉTODOS PARA RECONSTITUIÇçO DE LISE MEDIADA POR CÉLULA NK DE UMA CÉLULA ALVO EM UMA POPULAÇçO, PARA AVALIAÇçO DE UM ANTICORPO CONTRA NKG2A DE HUMANO, PARA PRODUÇçO DE UM ANTICORPO, PARA IDENTIFICAÇçO DE UM REGIME DE ADMIMSTRAÇçO ADEQUADO PARA UM ANTICORPO TERAPÊUTICO, PARA MATANÇA DE UMA CÉLULA NK, REDUÇçO DA ATIVIDADE DE UMA CÉLULA NK, REDUÇçO DA PROLIFERAÇçO DE CÉLULAS NK, PREVENÇçO DA USE DE CÉLULAS SUSCETÍVEIS À LISE POR CÉLULA NK, OU REDUÇçO DO NUMERO DE CÉLULAS NK EM UMA POPULAÇçO, E PARA DETECÇçO DA LIGAÇçO DE UM ANTICORPO EM NKG2A, USO DE UMA COMPOSIÇçO, CONJUGADO, E, KIT. A presente invenção refere-se aos métodos de tratar distúrbios imunes, particularmente distúrbios inflamatórios ou autoimunes, e aos métodos de produzir anticorpos e outros compostos para uso em estratégias terapêuticas para tratar tais distúrbios. Geralmente, os presentes métodos envolvem o uso de anticorpos ou de outros compostos que previnem a estimulação de receptores NKG2ç sobre células NK, acarretando a use de células dendriticas que contribuem para a patologia dos distúrbios.
BRPI0519420-2A 2004-12-28 2005-12-27 anticorpo, composiÇço, mÉtodos para reconstituiÇço de lise mediada por cÉlula nk de uma cÉlula alvo em uma populaÇço, para avaliaÇço de um anticorpo contra nkg2a de humano, para produÇço de um anticorpo, para identificaÇço de um regime de administraÇço adequado para um anticorpo terapÊutico, para matanÇa de uma cÉlula nk, reduÇço da atividade de uma cÉlula nk, reduÇço da proliferaÇço de cÉlulas nk, prevenÇço da lise de cÉlulas suscetÍveis À lise por cÉlula nk, ou reduÇço do némero de cÉlulas nk em uma populaÇço, e para detecÇço da ligaÇço de um anticorpo em nkg2a, uso de uma composiÇço, conjugado, e, kit BRPI0519420A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63983204P 2004-12-28 2004-12-28
US63946504P 2004-12-28 2004-12-28
PCT/IB2005/004013 WO2006070286A2 (en) 2004-12-28 2005-12-27 Monoclonal antibodies against nkg2a

Publications (1)

Publication Number Publication Date
BRPI0519420A2 true BRPI0519420A2 (pt) 2009-01-20

Family

ID=36350427

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519420-2A BRPI0519420A2 (pt) 2004-12-28 2005-12-27 anticorpo, composiÇço, mÉtodos para reconstituiÇço de lise mediada por cÉlula nk de uma cÉlula alvo em uma populaÇço, para avaliaÇço de um anticorpo contra nkg2a de humano, para produÇço de um anticorpo, para identificaÇço de um regime de administraÇço adequado para um anticorpo terapÊutico, para matanÇa de uma cÉlula nk, reduÇço da atividade de uma cÉlula nk, reduÇço da proliferaÇço de cÉlulas nk, prevenÇço da lise de cÉlulas suscetÍveis À lise por cÉlula nk, ou reduÇço do némero de cÉlulas nk em uma populaÇço, e para detecÇço da ligaÇço de um anticorpo em nkg2a, uso de uma composiÇço, conjugado, e, kit

Country Status (18)

Country Link
US (5) US8993319B2 (pt)
EP (3) EP2476705B1 (pt)
JP (2) JP5721304B2 (pt)
KR (1) KR101564713B1 (pt)
CN (1) CN102977213B (pt)
AU (1) AU2005321017B2 (pt)
BR (1) BRPI0519420A2 (pt)
CA (1) CA2591059C (pt)
DK (2) DK2476705T3 (pt)
ES (2) ES2557325T5 (pt)
FI (1) FI1831258T4 (pt)
HU (2) HUE026107T2 (pt)
IL (1) IL184152A (pt)
MX (1) MX2007007935A (pt)
NO (1) NO346624B1 (pt)
PT (2) PT1831258E (pt)
RU (1) RU2481356C2 (pt)
WO (1) WO2006070286A2 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412138B8 (pt) 2003-07-02 2021-05-25 Innate Pharma método de selecionar um anticorpo monoclonal, método de selecionar um anticorpo monoclonal ou seu fragmento de ligação em antígeno, método de detectar a presença de células nk, e, método de purificar de uma amostra células nk
KR101564713B1 (ko) 2004-12-28 2015-11-06 이나뜨 파르마 Ｎｋｇ2ａ에 대한 단클론 항체
TWI544076B (zh) 2005-03-31 2016-08-01 中外製藥股份有限公司 A method of manufacturing a polypeptide that controls assembly
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
CN103272232B (zh) 2006-06-08 2018-07-24 中外制药株式会社 炎性疾病的预防或治疗药
RU2499001C2 (ru) 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
US8057795B2 (en) * 2006-11-21 2011-11-15 Children's Research Institute Method of reducing the activation of Th2 lymphocytes
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
PE20091205A1 (es) * 2007-09-26 2009-09-09 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6
CN101939025B (zh) 2007-12-05 2015-03-25 中外制药株式会社 搔痒症治疗药
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
WO2010107109A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI457134B (zh) * 2009-03-19 2014-10-21 Chugai Pharmaceutical Co Ltd Rheumatoid arthritis treatment
WO2011037158A1 (ja) * 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
RU2012139181A (ru) 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
EP2588498B1 (en) 2010-06-29 2018-07-11 Centre National de la Recherche Scientifique (CNRS) Llt-1 antibodies with new functional properties
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
WO2012160448A2 (en) * 2011-05-25 2012-11-29 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory disorders
CN103635487B (zh) * 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2016032334A1 (en) * 2014-08-28 2016-03-03 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
EP4368205A1 (en) * 2014-09-16 2024-05-15 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
CN107074950A (zh) * 2014-09-16 2017-08-18 依奈特制药公司 使用抗nkg2a抗体的治疗方案
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016149103A1 (en) * 2015-03-13 2016-09-22 The Regents Of The University Of California Monoclonal antibody for prevention and/or treatment of astrovirus disease
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
KR102514173B1 (ko) 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2016186154A1 (ja) 2015-05-19 2016-11-24 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
WO2017125532A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
DE102017001875A1 (de) * 2017-02-27 2018-08-30 Wolfgang Würfel Medikament zur Malignombehandlung
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
KR102771895B1 (ko) 2017-10-20 2025-02-21 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
JP7531404B2 (ja) 2018-05-15 2024-08-09 メディミューン リミテッド 癌の処置
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
TW202033555A (zh) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 抗nkg2a抗體及其用途
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
KR20220032513A (ko) * 2019-03-29 2022-03-15 드렌 바이오, 인크. 거대 과립 림프구 및 자연 살해 세포 수준을 감소시키는 방법
JP7501876B2 (ja) 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
EP3990009A1 (en) 2019-06-27 2022-05-04 CRISPR Therapeutics AG Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation
CN113583127A (zh) * 2020-04-30 2021-11-02 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
EP4159236A4 (en) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
JP2023514386A (ja) * 2020-06-11 2023-04-05 南京北恒生物科技有限公司 Ｎｋ阻害性分子を発現する遺伝子改変免疫細胞とその使用
EP4171585A1 (en) 2020-06-26 2023-05-03 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
WO2022072508A1 (en) 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4267105B1 (en) 2020-12-28 2025-03-26 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CN118871451A (zh) 2022-03-18 2024-10-29 百时美施贵宝公司 分离多肽的方法
CN119562830A (zh) 2022-06-02 2025-03-04 百时美施贵宝公司 抗体组合物及其使用方法
WO2024056010A1 (zh) * 2022-09-16 2024-03-21 北京三诺佳邑生物技术有限责任公司 特异性识别nkg2a的抗体及其应用
CN120936378A (zh) * 2023-01-27 2025-11-11 埃克塞里艾克西斯公司 Nkg2a结合剂和其用途
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024260280A1 (en) * 2023-06-21 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to nkg2a and uses thereof
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
CN117143815B (zh) * 2023-10-30 2024-01-26 再少年(北京)生物科技有限公司 工程化记忆样nk细胞的制备方法及应用
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025168052A1 (en) * 2024-02-08 2025-08-14 Hanx Biopharmaceuticals, (Wuhan) Ltd. Nkg2a/cd94-targeting antibodies and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112484A (ja) 1989-09-26 1991-05-14 Nisshin Seito Kk 新規制限酵素及びその製造方法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3112484B2 (ja) 1990-01-17 2000-11-27 テルモ株式会社 医療容器
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JP3112487B2 (ja) 1990-10-12 2000-11-27 オリンパス光学工業株式会社 画像フリーズ用信号処理装置
JP3112485B2 (ja) 1991-01-22 2000-11-27 オリンパス光学工業株式会社 立体電子スチルカメラ
JP3112486B2 (ja) 1991-02-06 2000-11-27 大日本印刷株式会社 感圧複写紙
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
AU701342B2 (en) * 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
WO1997041898A1 (en) 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
KR100816572B1 (ko) 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
AU783899B2 (en) 1999-11-15 2005-12-22 Innate Pharma S.A.S. Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
CA2406993A1 (en) 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6999941B1 (en) 2000-07-11 2006-02-14 Amazon.Com, Inc. Providing gift clustering functionality to assist a user in ordering multiple items for a recipient
ATE556092T1 (de) 2000-12-18 2012-05-15 Inst Nat Sante Rech Med Mittel zur diagnose und therapie von ctcl
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
JP4326944B2 (ja) 2001-07-19 2009-09-09 イネイト・ファーマ ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ
CA2456196A1 (en) 2001-07-31 2003-02-13 Karl Petter Soderstrom Compositions and methods for modulation of immune responses
AU2003233894A1 (en) 2002-05-13 2003-11-11 Envirotech Products Limited Tank valve testing method
BR0311471A (pt) 2002-05-30 2007-04-27 Macrogenics Inc anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
CN1751236A (zh) 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005115517A2 (en) 2004-04-28 2005-12-08 Joslin Diabetes Center, Inc. Methods of treating diabetes
JP2008502597A (ja) 2004-04-30 2008-01-31 イネイト・ファーマ Ｎｋ型ｌｄｇｌのような免疫増殖性障害を処置するための組成物および方法
KR101564713B1 (ko) 2004-12-28 2015-11-06 이나뜨 파르마 Ｎｋｇ2ａ에 대한 단클론 항체
CN101107269B (zh) 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
JP3112484U (ja) 2005-05-13 2005-08-18 浩志 柯 熱交換器の構造
JP3112487U (ja) 2005-05-13 2005-08-18 株式会社國光社 手動式篩い器
JP3112486U (ja) 2005-05-13 2005-08-18 高北 孝 履物整頓具
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
RU2499001C2 (ru) * 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
RU2012139181A (ru) 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞

Also Published As

Publication number Publication date
FI1831258T4 (fi) 2023-08-31
WO2006070286A3 (en) 2006-08-31
EP1831258B2 (en) 2023-06-07
US8993319B2 (en) 2015-03-31
KR20070094945A (ko) 2007-09-27
IL184152A (en) 2015-03-31
RU2481356C2 (ru) 2013-05-10
ES2557325T3 (es) 2016-01-25
JP2013028640A (ja) 2013-02-07
CN102977213B (zh) 2017-05-24
NO20073063L (no) 2007-09-28
HK1108458A1 (zh) 2008-05-09
US10160810B2 (en) 2018-12-25
JP6054129B2 (ja) 2016-12-27
EP1831258A2 (en) 2007-09-12
WO2006070286A2 (en) 2006-07-06
EP2476705B1 (en) 2015-10-07
DK1831258T3 (en) 2016-01-11
JP5721304B2 (ja) 2015-05-20
DK2476705T3 (en) 2015-12-14
JP2008525520A (ja) 2008-07-17
IL184152A0 (en) 2007-10-31
ES2557325T5 (es) 2023-11-15
EP2476705A1 (en) 2012-07-18
RU2007129033A (ru) 2009-02-10
US20150125464A1 (en) 2015-05-07
DK1831258T4 (en) 2023-08-28
US20090208416A1 (en) 2009-08-20
MX2007007935A (es) 2007-12-06
HUE026688T2 (en) 2016-07-28
PT2476705E (pt) 2016-02-09
CA2591059C (en) 2018-11-06
CN102977213A (zh) 2013-03-20
ES2557587T3 (es) 2016-01-27
NO346624B1 (no) 2022-11-07
EP3026063A1 (en) 2016-06-01
AU2005321017B2 (en) 2011-02-24
AU2005321017A2 (en) 2006-07-06
CA2591059A1 (en) 2006-07-06
KR101564713B1 (ko) 2015-11-06
EP1831258B1 (en) 2015-10-14
US20110229486A1 (en) 2011-09-22
PT1831258E (pt) 2016-01-07
HUE026107T2 (en) 2016-05-30
US20150132316A1 (en) 2015-05-14
US20190135938A1 (en) 2019-05-09
AU2005321017A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
BRPI0519420A2 (pt) anticorpo, composiÇço, mÉtodos para reconstituiÇço de lise mediada por cÉlula nk de uma cÉlula alvo em uma populaÇço, para avaliaÇço de um anticorpo contra nkg2a de humano, para produÇço de um anticorpo, para identificaÇço de um regime de administraÇço adequado para um anticorpo terapÊutico, para matanÇa de uma cÉlula nk, reduÇço da atividade de uma cÉlula nk, reduÇço da proliferaÇço de cÉlulas nk, prevenÇço da lise de cÉlulas suscetÍveis À lise por cÉlula nk, ou reduÇço do némero de cÉlulas nk em uma populaÇço, e para detecÇço da ligaÇço de um anticorpo em nkg2a, uso de uma composiÇço, conjugado, e, kit
Chacon‐Cabrera et al. Pharmacological strategies in lung cancer‐induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness
AU2015334468B2 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
Yuan et al. Tetrandrine ameliorates collagen-induced arthritis in mice by restoring the balance between Th17 and Treg cells via the aryl hydrocarbon receptor
IL260135A (en) Preparations and methods of neisseria meningitidis
CN115515610A (zh) 使用栖组织普雷沃菌治疗银屑病和特应性皮炎的组合物和方法
BR112013002940A2 (pt) adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
IL173477A (en) A multispecific antibody comprising binding arms that binds two different antigens on the same target cell and its use in the preparation of a pharmaceutical preparation
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
CN120098930A (zh) 工程化的免疫细胞的应用和生产
Shin et al. Impaired adrenergic agonist‐dependent beige adipocyte induction in aged mice
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
Cavalcante et al. Role of NMDA receptors in the trigeminal pathway, and the modulatory effect of magnesium in a model of rat temporomandibular joint arthritis
WO2005085323A3 (en) Methods and compositions for treatment of autoimmune diseases
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
Miyagi et al. Dimethyl fumarate attenuates oxaliplatin-induced peripheral neuropathy without affecting the anti-tumor activity of oxaliplatin in rodents
BR112019008844A2 (pt) conjugado de proteína de polissacarídeo imunogênico compreendendo um polissacarídeo derivado de b. streptococcus gbs
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
BR112022020639A2 (pt) Anticorpos anti-dectina-2
Pablos‐Tanarro et al. Egg yolk provides Th2 adjuvant stimuli and promotes sensitization to egg white allergens in BALB/c mice
EP2392674A3 (en) Cellular biomarker antioxidant assay and uses thereof
Liu et al. Lion's mane medicinal mushroom, Hericium erinaceus (Agaricomycetes), modulates purinoceptor-coupled calcium signaling and murine nociceptive behavior

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]

Free format text: REPUBLICACAO DO PARECER 7.1 DA RPI NO 2522 DE 07/05/2019.

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL